XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCK-BASED COMPENSATION
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION

 

11. STOCK-BASED COMPENSATION

 

Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, with expiration 10 years from the date they are granted, and generally vest over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to Board members and employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.

 

 

The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the nine-month periods ended September 30, 2022 and 2021.

 

  

   September 30, 2022   September 30, 2021 
   (unaudited) 
Risk-free interest rate   1.76%   0.78%
Expected life   6.0 years    6.0 years 
Expected volatility   129.93%   134.79%
Dividend yield   -    - 

 

During March 2021, the Company granted 312,500 stock options with an exercise price of $6.00 and 152,500 RSUs. The market value of the Company’s common stock was $5.00 at the grant date of these awards. The Company recognized approximately $0.5 million and $0.4 million of stock-based compensation expense within continuing operations during the three-month periods ended September 30, 2022 and 2021, respectively and approximately $1.1 million and $1.1 million of stock-based compensation expense during the nine-month periods ended September 30, 2022 and 2021, respectively. The following table has a breakout of stock-based compensation expense from continuing operations by line item.

 

  

   2022   2021   2022   2021 
   Three Months Ended   Nine Months Ended 
   September 30   September 30 
   2022   2021   2022   2021 
   (unaudited)   (unaudited) 
Cost of revenue  $19   $52   $67   $220 
Sales and marketing   42    76    128    201 
Research and development   -    24    -    83 
General and administrative*   440    276    915    635 
Total stock compensation expense  $501   $428   $1,110   $1,139 

 

* Includes ESPP expense